Literature DB >> 19355919

The role of leukotrienes in airway remodeling.

Anjuli K Mehrotra1, William R Henderson.   

Abstract

Asthma is an inflammatory disorder of the airways that has been typified by its bronchospastic component. New attention has been directed to the long-term changes in asthmatic airways as indicated by the accelerated rate of lung function decline occurring in these patients despite therapy with inhaled corticosteroids. These structural changes in the airway wall, termed airway remodeling, are now thought to be a key component in the pathophysiology of asthma. Airway remodeling is characterized by thickening of the lamina reticularis with deposition of collagen and other extracellular matrix proteins leading to subepithelial fibrosis and increased airway goblet cells causing mucus hypersecretion. Of note, there is myofibroblast proliferation and increased airway smooth muscle mass caused by both hyperplasia and hypertrophy of smooth muscle cells. While an important role for cysteinyl leukotrienes (CysLTs) in the pathogenesis of airway inflammation and bronchoconstriction in asthma has been well-established, the specific role of CysLTs in airway remodeling is less clear. This aim of this review is to summarize the data from mouse models of asthma as well as limited human studies that demonstrate a key role for CysLTs in allergen-induced mucus hypersecretion, thickening of the lamina reticularis, and subepithelial fibrosis in the lungs. We will also focus on the interaction between CysLTs and cytokines/growth factors that mediate these changes in epithelial cells, smooth muscle cells, vasculature, and other structural components of the lungs in patients with asthma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19355919     DOI: 10.2174/156652409787847209

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  8 in total

Review 1.  Does airway smooth muscle express an inflammatory phenotype in asthma?

Authors:  Gautam Damera; Reynold A Panettieri
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

2.  Allergen-induced airway remodeling is impaired in galectin-3-deficient mice.

Authors:  Xiao Na Ge; Nooshin S Bahaie; Bit Na Kang; M Reza Hosseinkhani; Sung Gil Ha; Elizabeth M Frenzel; Fu-Tong Liu; Savita P Rao; P Sriramarao
Journal:  J Immunol       Date:  2010-06-11       Impact factor: 5.422

3.  Secreted PLA2 group X orchestrates innate and adaptive immune responses to inhaled allergen.

Authors:  James D Nolin; Ying Lai; Herbert Luke Ogden; Anne M Manicone; Ryan C Murphy; Dowon An; Charles W Frevert; Farideh Ghomashchi; Gajendra S Naika; Michael H Gelb; Gail M Gauvreau; Adrian M Piliponsky; William A Altemeier; Teal S Hallstrand
Journal:  JCI Insight       Date:  2017-11-02

4.  Anti-inflammatory effects of the R2 peptide, an inhibitor of transglutaminase 2, in a mouse model of allergic asthma, induced by ovalbumin.

Authors:  Dae Yong Kim; Bum Soo Park; Gwan Ui Hong; Byung Jae Lee; Jung Won Park; Soo Youl Kim; Jai Youl Ro
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

5.  Fatty acids induce leukotriene C4 synthesis in macrophages in a fatty acid binding protein-dependent manner.

Authors:  Eric K Long; Kristina Hellberg; Rocio Foncea; Ann V Hertzel; Jill Suttles; David A Bernlohr
Journal:  Biochim Biophys Acta       Date:  2013-04-12

Review 6.  Role of Leukotrienes and Leukotriene Modifiers in Asthma.

Authors:  Paolo Montuschi
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-02

7.  Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial.

Authors:  David Ruttens; Stijn E Verleden; Heleen Demeyer; Dirk E Van Raemdonck; Jonas Yserbyt; Lieven J Dupont; Bart M Vanaudenaerde; Robin Vos; Geert M Verleden
Journal:  PLoS One       Date:  2018-04-06       Impact factor: 3.240

8.  Stimulus-selective regulation of human mast cell gene expression, degranulation and leukotriene production by fluticasone and salmeterol.

Authors:  Adriana Catalli; Victor Karpov; Levente E Erdos; Brian P Tancowny; Robert P Schleimer; Marianna Kulka
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.